Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

Inc. ( an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful ...

Industry leaders in health and science converged in downtown Raleigh Thursday to highlight the area’s latest advancements in ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

The U.S. Treasury Department said on Thursday that New York-based insurer MetLife's unit, American Life Insurance Company, ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...

Meanwhile, some companies such as Biogen, U.S. Bancorp and Western Midstream Partners ... Stepan (SCL) said it has appointed Luis Rojo as CEO and president, effective immediately.

On the “anniversary” of Leqembi’s broader launch last fall, Biogen CEO Chris Viehbacher said the company has already learned a great deal about what it will take for Leqembi to succeed ...